|
|
|
|
Vol. 57, Issue 2, 392-400, February 2000
KPQ Na+
Channel Mutant by Pilsicainide and Lidocaine with Distinct Mechanisms
Department of Physiology, Oita Medical University, Hasama, Oita
(K.O., T.K., M.A.); and Department of Cardiovascular Medicine, Hokkaido
University School of Medicine, Sapporo, Hokkaido (N.M., A.K.), Japan.
The congenital long QT syndrome is an inherited disorder characterized
by a delay in cardiac repolarization, leading to lethal cardiac
arrhythmias such as torsade de pointes. One form of this disease
involves mutations in the voltage-dependent cardiac Na+
channel, which includes an in-frame deletion of three amino acids (Lys-1505, Pro-1506, and Gln-1507;
KPQ). The potential for selective suppression of the mutant was examined by heterologous expression of
KPQ-Na+ channels in Chinese hamster fibroblast cells via
single-channel recording. In a single-channel cell-attached patch
study,
KPQ-Na+ channels yielded currents that peaked at
~1 ms after voltage steps to 0 mV with aberrant late currents, which
were composed of burst and isolated openings. The affinity of certain
anesthetics (pilsicainide and lidocaine) to the late currents of the
mutant channels was examined. It was revealed that 1) pilsicainide (1 µM), an open channel blocker of voltage-dependent Na+
channels, remarkably decreased the late currents primarily by the
shortening of burst duration without suppressing the initial peak
current; and 2) lidocaine (1 µM), an inactivated channel blocker,
decreased the late currents primarily by the suppression of isolated
channel openings. Because the late currents in
KPQ mutants are
mainly composed of the burst openings, we conclude that pilsicainide is
capable of selectively blocking the late currents in the mutant
Na+ channels that show dominant abnormal burst openings
such as in
KPQ mutants.